Viridian Therapeutics partners with Kissei Pharmaceutical to advance treatments for thyroid eye disease in Japan, enhancing patient care and market potential.

President Trump published letters to 17 major pharma companies reiterating his requirements for them to fulfill his MFN order ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...

The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

Zura Bio’s CEO and director Robert Lisicki discusses how his path to leadership taught him the importance of building a team ...

The survey reveals how financial anxiety has become an everyday occurrence affecting everyday health through stress, ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.